Background Daratumumab is a first-in-class anti-CD38 monoclonal antibody approved for
multiple myeloma. Because of the incidence and severity of infusion-related reactions with …

Introduction/background Daratumumab is an anti-CD38 monoclonal antibody initially
approved as a single agent for the treatment of relapsed and refractory multiple myeloma …

Daratumumab demonstrates activity as a single agent and in combination with either
immunomodulatory agents (IMiDs) or proteasome inhibitors (PIs) in relapsed refractory …

Outside of clinical trials, experience with daratumumab‐based combination therapies
(DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and dexamethasone (d) in …

Daratumumab-based therapy has been shown to have significant clinical efficacy in phase 3
trials of patients with relapse or refractory multiple myeloma. Outside of clinical trials …

New therapeutic strategies are urgently needed to improve clinical outcomes in patients with
multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ …

Background Daratumumab is a human CD38‐directed monoclonal antibody indicated for
the treatment of relapsed and refractory multiple myeloma (MM). Methods A multicenter …

Patients with relapsed or refractory multiple myeloma (RRMM) have limited treatment
options and poor survival outcomes. The increasing adoption of lenalidomide-based therapy …

Background Daratumumab, a CD38 monoclonal antibody, has demonstrated efficacy as
monotherapy and combination therapy across several indications, both among newly …

Purpose Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for
recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) …